Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis.

Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018 Jan 29;: Authors: Scaioli E, Sartini A, Bellanova M, Campieri M, Festi D, Bazzoli F, Belluzzi A Abstract BACKGROUND & AIMS: High fecal levels of calprotectin indicate mucosal inflammation and have been shown to predict relapse in patients with ulcerative colitis (UC). Eicosapentaenoic acid (EPA), the major component of n-3 fish oil, has anti-inflammatory properties in patients with chronic inflammatory disorders. We performed a placebo-controlled trial of patients with UC at…

Read More

Symptoms do not Correlate With Findings From Colonoscopy in Children with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Symptoms do not Correlate With Findings From Colonoscopy in Children with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2018 Jan 25;: Authors: Ricciuto A, Fish J, Carman N, Walters TD, Church PC, Hansen BE, Crowley E, Siddiqui I, Nguyen GC, Kamath BM, Griffiths AM Abstract BACKGROUND & AIMS: Approximately 75% of children with primary sclerosing cholangitis (PSC) also have inflammatory bowel disease (IBD). IBD in patients with PSC (PSC-IBD) often has a unique phenotype, including a mild clinical course, yet it is associated with an increased risk…

Read More

The unregulated probiotic market.

The unregulated probiotic market. Clin Gastroenterol Hepatol. 2018 Jan 25;: Authors: de Simone C Abstract BACKGROUND AND AIMS: This narrative review provides an overview of the current regulation of probiotics, with a focus on those used for the dietary management of medical conditions (Medical Foods). FINDINGS: The probiotic market has grown rapidly, both for foods and supplements intended to enhance wellness in healthy individuals, and for preparations for the dietary management of disease. Regulation of probiotics varies between regions. Unless they make specific disease-related health claims, probiotics are regulated as…

Read More

High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease.

High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018 Jan 25;: Authors: Shah SC, Ten Hove JR, Castaneda D, Palmela C, Mooiweer E, Colombel JF, Harpaz N, Ullman TA, van Bodegraven AA, Jansen JM, Mahmmod N, van der Meulen-de Jong AE, Ponsioen CY, van der Woude CJ, Oldenburg B, Itzkowitz SH, Torres J Abstract BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC, termed PSC-IBD) are at increased risk for colorectal cancer (CRC),…

Read More

Efficacy of Medical Therapies for Fistulizing Crohn’s Disease: Systematic Review and Meta-analysis.

Efficacy of Medical Therapies for Fistulizing Crohn’s Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018 Jan 25;: Authors: Lee MJ, Parker CE, Taylor SR, Guizzetti L, Feagan BG, Lobo AJ, Jairath V Abstract BACKGROUND & AIMS: Fistulas are debilitating complications of Crohn’s disease (CD) that affect up to 50% of patients. We conducted a systematic review and meta-analysis of randomized controlled trials to assess the efficacy of treatments for fistulizing CD. METHODS: We searched publication databases from inception through December 13, 2016 for trials comparing the efficacy of a…

Read More

Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.

Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2018 Jan 05;: Authors: Khan N, Patel D, Trivedi C, Shah Y, Lichtenstein G, Lewis J, Yang YX Abstract BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) might be at increased risk for herpes zoster infection. We sought to quantify the risk of herpes zoster in patients with IBD and evaluate the effects of IBD and IBD medications on the risk of herpes zoster. METHODS: We conducted 2 retrospective…

Read More

Epithelioid Granulomas Associate with Increased Severity and Progression of Crohn’s Disease, Based on 6-year Follow Up.

Related Articles Epithelioid Granulomas Associate with Increased Severity and Progression of Crohn’s Disease, Based on 6-year Follow Up. Clin Gastroenterol Hepatol. 2017 Dec 22;: Authors: Johnson CM, Hartman DJ, Ramos-Rivers C, Rao BB, Bhattacharya A, Regueiro M, Schwartz M, Swoger J, Al Hashash J, Barrie A, Pfanner TP, Dunn M, Koutroubakis IE, Binion DG Abstract BACKGROUND & AIMS: Epithelioid granulomas are characteristics of a subset of patients with Crohn’s disease (CD), but their significance, with regard to disease progression and severity, is unclear. We investigated the relationship between granulomas and…

Read More

Association of Vedolizumab Level, Anti-drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.

Association of Vedolizumab Level, Anti-drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2017 Dec 06;: Authors: Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, Coscas D, Waterman M, Haj-Natour O, Orbach-Zingboim N, Mao R, Chen M, Chowers Y, Eliakim R, Ben-Horin S Abstract BACKGROUND & AIMS: There are few data available on the real-life pharmacokinetic and pharmacodynamics features of vedolizumab, a monoclonal antibody against integrin α4β7. We performed a prospective study of patients with inflammatory bowel diseases (IBD)…

Read More
<< Go Back